1) neointima hyperplasia
新生内膜增殖
1.
The purposes of this study was to determine the effects of recombinant human interleukin-10 (rhIL-10) on proliferation of vascular smooth muscle cells (VSMCs) stimulated by advanced glycation end products (AGE) and neointima hyperplasia after rat carotid arterial injury.
研究观察了重组人白介素 10 (rhIL 10 )对晚期糖基化终产物 (AGE)刺激下离体大鼠胸主动脉血管平滑肌细胞增殖及对SD大鼠血管损伤后新生内膜增殖的影响。
2) Intimal hyperplasia
内膜增殖
1.
RT-PCR, immunohistochemical staining and histochemical staining were used to detect the c-myc mRNA, Ki67 antigen and the degree of intimal hyperplasia.
目的评估酪氨酸蛋白激酶抑制剂2,5-MC抑制支架植入术后内膜增殖的效果。
2.
Objective and backgroundInflammation and platelet may be very important in the progress of intimal hyperplasia, and the letter is the principle mechanism of restenosis after PTC A.
流行病学、基础及临床实验均表明肺炎衣原体(CP)与动脉粥样硬化(AS)及血管内膜增殖有关。
3) intimal proliferation
内膜增殖
1.
The rat model of intimal proliferation were copied by injuring aortic intima with self-made balloon.
各组采用球囊内膜剥脱法复制大鼠主动脉内膜增殖动物模型,每组自造模前1 d开始,分别静脉注射化瘀通脉注射液、丹参注射液和生理盐水,于造模后第5,10,15,25 d每组各随机选取8只大鼠取血,检测各组血浆ET-1、NOI、CAM-1含量。
2.
Objective: To study the effect of Huayutongmai Injection on intimal proliferation of rat aorta after balloon injury.
目的:观察化瘀通脉注射液对大鼠主动脉球囊损伤后内膜增殖的影响。
3.
Intimal proliferation is a leading cause of restenosis after percutaneous coronary intervention.
内膜增殖是经皮冠状动脉介入治疗后再狭窄的主要原因,包括中膜血管平滑肌细胞表型转化、增殖、迁移至内膜并合成大量的细胞外基质。
4) neointima formation
内膜增殖
1.
Influence of bone marrow-derived EPCs to neointima formation;
大鼠骨髓源性内皮祖细胞对损伤后血管内膜增殖的影响
5) neointimal proliferation
内膜增殖
1.
Effectiveness of recombinant hirudin locally delivered via a porous balloon on lessening neointimal proliferation and luminal stenosis after balloon angioplasty in rabbits;
重组水蛭素局部治疗球囊扩张术后内膜增殖和管腔狭窄的实验研究
2.
Effectiveness of recombinant hirudin locally delivered via a porous balloon on reducing neointimal proliferation and luminal stenosis after balloon angioplasty in a rabbit model;
重组水蛭素局部治疗兔髂总动脉球囊扩张术后内膜增殖和管腔狭窄
3.
Effect of recombinant hirudin in reducing neointimal proliferation after balloon angioplasty of normal iliac arteries in rabbits;
重组水蛭素对兔髂总动脉球囊损伤后内膜增殖影响的实验研究
6) Neointimal hyperplasia
新生内膜增生
1.
Objective①to evaluate the effect of sirolimus and paclitaxel on neointimal hyperplasia andvessel wall remodeling after PTA.
目的：评价雷帕霉素、紫杉醇等抗增殖药物对血管成形术(percutaneous transluminalangioplasty，PTA)后新生内膜增生及血管重塑的影响；评价雷帕霉素、紫杉醇对PTA后血管内皮化及血管壁凝血相关因子的影响；比较不同给药方式下紫杉醇对PTA后新生内膜增生及血管壁凝血相关因子的影响。
2.
Objective:To preliminarily investigate the influence of Rosuvastatin on the neointimal hyperplasia and its mechanism in rat carotid arteries after balloon injury.
目的:初步探讨瑞舒伐他汀对大鼠颈动脉球囊损伤后新生内膜增生的影响及其作用机制。
补充资料：子宫内膜癌腔内放射治疗
子宫内膜癌腔内放射治疗
子宫内膜癌腔内放疗有：①传统方法，使用治疗子宫颈癌的治疗容器，如宫腔管及阴道容器，(容器有：斯德哥尔摩盒式、巴黎弓形、曼彻斯特卵圆形、北京型等)。其缺点是子宫角部受量不足；②Heyman倡导宫腔填充法，将含有镭或其他同位素的金属小囊填满于子宫腔内，使宫腔各壁均能得到高剂量照射，可使单纯放疗效果由30%～40%增至60%以上；③腔内后装放射治疗。剂量：现在采用高剂量率及中剂量率，摒弃低剂量率。高剂量率：Ⅰ期：A点(位于子宫旁三角区内，代表宫旁正常组织受量)总剂量36～40Gy，F点(位于宫腔放射源的顶端旁开子宫中轴2cm，代表肿瘤部受量)总剂量40～45Gy。腔内治疗分5～6次进行，每周1次，每次剂量大致相同。Ⅱ期～Ⅲ期：A点及F点总剂量均为45～50Gy，腔内治疗分6～7次，每周1次，每次剂量大致相同。中剂量率：Ⅰ期：A点总剂量率45～50Gy，F点总剂量50～55Gy，腔内治疗6～8次，每周1次，每次剂量基本相似，Ⅱ～Ⅲ期：A点及F点剂量均为55～60Gy，腔内治疗7～8次，每周1次，每次剂量大致相同。腔内照射多用137Cs、60Co等。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条